Novartis, CH0012005267

Novartis raises 2026 core income guidance for Novartis stock

Published on 10/27/2026 at 10:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis lifted its 2026 core income view from decline to growth. Novartis stock costs EUR 140.03 on October 27, 2026.

Guidance improves despite impairment

On October 27, 2026, Novartis raised its full-year core operating income outlook.
Third-quarter net sales reached USD 14.52 billion, up 4 percent year over year.
Novartis stock traded at EUR 140.03 at 10:09 a.m. CET at Lang & Schwarz on October 27, 2026.
Management events are scheduled for November 18-19, 2026.

Novartis, CH0012005267, Illustration mit AI erstellt.

Novartis (ISIN CH0012005267) raised its full-year 2026 core operating income outlook on October 27, 2026, while third-quarter net income fell 70 percent to USD 1.20 billion. The announcement came with quarterly sales growth and a wider core margin, according to Novartis.

Guidance improves as profit falls

Novartis now expects full-year core operating income to remain in line with the prior year or grow by a low single-digit percentage at constant exchange rates. The previous outlook called for a low single-digit decline. Full-year net sales growth remains projected in the low single-digit range, as reported by Morningstar.

Third-quarter net sales increased 4 percent to USD 14.52 billion from USD 13.91 billion in the same period of 2025. Core operating income rose 11 percent to USD 6.04 billion, and the core operating margin reached 41.6 percent, up from 39.3 percent a year earlier. The comparison is more favorable before exceptional charges.

What does the impairment mean for margins?

The reported earnings decline was driven in part by a USD 1.90 billion partial impairment of the del-desiran research asset. Core operating income still advanced because higher sales and productivity gains outweighed generic competition, but the impairment shows how clinical setbacks can widen the gap between adjusted and reported results.

Three dated developments

On October 21, 2026, Novartis received European Commission approval for Cosentyx in polymyalgia rheumatica. On October 23, 2026, the company held an investor call on remibrutinib in multiple sclerosis. On October 27, 2026, it reported USD 14.52 billion in third-quarter sales and raised its core operating income outlook, according to Novartis.

Next dates for investors

Novartis lists Meet Novartis Management 2026 for November 18-19, 2026, in London. Fourth-quarter and full-year 2026 results are scheduled for February 3, 2027, followed by the annual general meeting on March 5, 2027.

Stock price after the results

The latest market signal is the euro quotation rather than a fundamental revaluation: Novartis stock was trading at EUR 140.03 at Lang & Schwarz on October 27, 2026, at 10:09 a.m. CET. The next price reaction will depend on whether investors give greater weight to the raised core outlook or the impairment-driven decline in reported profit.

The further course of trading is shown by the continuously updated real-time quote of Novartis stock.